- The i/Blue Imaging System’s(TM) development is the first to harness the power of white light and blue light visualization techniques with the added capability of displaying multiple images simultaneously which will help surgeons perform more accurate tumor resections
- Imagin Medical’s innovative system is currently in the manufacturing phase with Lighthouse Imaging with product completion slated for 2022
- With its patented technology, the company is positioned to stake a claim on a $400 million segment of the $46 billion global endoscopy market
Advancements in the way that cancer is diagnosed and treated continue to be made. On the forefront of new technological innovation for visualizing cancer is Imagin Medical (CSE: IME) (OTCQB: IMEXF) i/Blue(TM) Imaging System, a technology designed to combine the advantages of traditional white light with blue light imaging to provide unparalleled visualization for removal of bladder cancer.
Bladder cancer is the sixth most prevalent cancer found in the United States and has one of the highest recurrence rates. The American Cancer Society estimates there will be...
NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at http://ibn.fm/IMEXF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text "STOCKS" to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.